A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis

Background Teriflunomide is a once-daily oral immunomodulator for the treatment of relapsing−remitting MS. Objective To evaluate the safety and tolerability of teriflunomide as add-on therapy to a stable dose of glatiramer acetate (GA) in patients with relapsing forms of MS (RMS). Methods Phase II,...

Celý popis

Podrobná bibliografie

Hlavní autoři:	MS Freedman, JS Wolinsky, P Truffinet, G Comi, L Kappos, AE Miller, TP Olsson, M Benamor, S Chambers, PW O’Connor
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SAGE Publishing 2015-12-01
Edice:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
On-line přístup:	https://doi.org/10.1177/2055217315618687
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!